PERL is a 3-year clinical trial investigating whether the uric acid lowering drug allopurinol can preserve kidney function among type 1 diabetic patients. The PERL study has been funded by the NIDDK and has been ongoing at 16 clinical sites across the US, Canada, and Europe (the Joslin Diabetes Center, the Universities of Minnesota, Colorado, Michigan, Washington, Texas Southwestern, Toronto, Calgary, and Alberta, Northwestern University, Albert Einstein College of Medicine, Washington University in St. Louis, Emory University, BC Diabetes [Vancouver], Providence Sacred Heart Medical Center [Spokane],and the Steno Diabetes Center in Copenhagen, Denmark).” Continuation of PERL funding beyond 12/1/17 ad until 11/30/19 is being sought though an application to NIH in response to RFA-DK-16-506. During the continuation period, the PERL site at Northwestern University will continue to treat and follow PERL participants enrolled at that location according to the procedures described in the PERL protocol and in the Manual of Operations and to the Good Clinical Practice guidelines. Special effort will be placed on maximizing participants’ adherence and retention in the study. The Site Director and study coordinator(s) will continue to participate in study-wide activities such as Steering Committee teleconferences, Study Coordinators teleconferences, and yearly in-person meetings. They will interact with the Data Coordinating Center to resolve data queries. In the last five months, the Site Director will contribute to result interpretation and manuscript writing.
|Effective start/end date||9/15/17 → 6/30/19|
- Joslin Diabetes Center, Inc. (100062//2UC4DK101108-02)
- National Institute of Diabetes and Digestive and Kidney Diseases (100062//2UC4DK101108-02)